Scarica l'app Stockscreener
6.18
3.82%
-0.25
Precedente Chiudi:
$6.43
Aprire:
$6.64
Volume 24 ore:
2.32M
Relative Volume:
1.11
Capitalizzazione di mercato:
$450.72M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-1.3233
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
-16.88%
1M Prestazione:
-20.61%
6M Prestazione:
-66.93%
1 anno Prestazione:
-74.62%
Intervallo 1D:
$6.055
$6.64
Intervallo di 1 settimana:
$6.055
$7.83
Portata 52W:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.175 | 555.46M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.83 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.00 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.63 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.94 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.00 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes - MSN
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - Stocktwits
Arvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Guggenheim lowers Arvinas stock price target to $15 on partnership concerns - Investing.com
Insider Sellers Might Regret Selling Arvinas Shares at a Lower Price Than Current Market Value - simplywall.st
Arvinas Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by XTX Topco Ltd - MarketBeat
Federated Hermes Inc. Purchases 933,183 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Reports Q2 2025 Financials and Drug Developments - TipRanks
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas Q2 2025 Earnings Call Transcript - MarketBeat
ARVINAS, INC. SEC 10-Q Report - TradingView
Earnings call transcript: Arvinas Q2 2025 results show revenue miss, stock drops - Investing.com Canada
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Arvinas earnings beat by $0.10, revenue fell short of estimates - Investing.com Canada
Arvinas Inc (ARVN) Q2 2025 Earnings: EPS Beats Estimates at -$0. - GuruFocus
What To Expect From Arvinas Inc (ARVN) Q2 2025 Earnings - Yahoo Finance
What drives Arvinas Inc. stock priceFind market-beating stocks for your portfolio - Jammu Links News
What are the technical indicators suggesting about Arvinas Inc.Unlock the power of real-time market data - Jammu Links News
Arvinas (NASDAQ:ARVN) Stock Price Up 8.6%Time to Buy? - MarketBeat
What are the latest earnings results for Arvinas Inc.High-impact stock picks - Jammu Links News
Is Arvinas Inc. a good long term investmentBuild wealth faster with consistent investment plans - Jammu Links News
What is Arvinas Inc. company’s growth strategyAchieve rapid portfolio growth with smart picks - Jammu Links News
What is the dividend policy of Arvinas Inc. stockCapitalize on proven investment strategies - Jammu Links News
How does Arvinas Inc. generate profit in a changing economyGet real-time alerts on high-potential stocks - Jammu Links News
What catalysts could drive Arvinas Inc. stock higher in 2025Tremendous portfolio expansion - Jammu Links News
Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Boosted by Monaco Asset Management SAM - MarketBeat
What makes Arvinas Inc. stock price move sharplyUnlock powerful insights from market experts - Jammu Links News
Does Arvinas Inc. stock perform well during market downturnsCapitalize on momentum-driven stocks - Jammu Links News
Arvinas Inc. Could See a Relief Rally From SupportHigh Return Stock Focus With Safety Emphasized - metal.it
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 - 富途牛牛
Should I hold or sell Arvinas Inc. stock in 2025Earnings Report Opportunities To Watch Now - Jammu Links News
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Yahoo Finance
Investors in Arvinas (NASDAQ:ARVN) have unfortunately lost 86% over the last three years - Yahoo Finance
Is Arvinas Inc. the Top Chart Pick This WeekBig Return Stock Tips - beatles.ru
Arvinas, Inc. to Host Q2 2025 Financial Results and Corporate Update Webcast on August 6, 2025 - Quiver Quantitative
Protein Degradation Pioneer Arvinas Sets Q2 2025 Earnings Report DateKey Details Inside - Stock Titan
Using data filters to optimize entry into Arvinas Inc.News Based Entry Opportunity Alerts Detected - metal.it
Leerink Partners Reaffirms Hold Rating on Arvinas Holding Company Amid Mixed Analyst Sentiment - AInvest
Watch for Bullish Crossover in Arvinas Inc.Risk Adjusted Technical Entry Plan Gains Followers - metal.it
Published on: 2025-07-29 21:05:33 - metal.it
Technical Bounce Expected in Arvinas Inc. Next WeekTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):